Shares of Lincoln Pharmaceuticals Ltd. are trading lower on Thursday, November 13, after the company reported a decline in profit and operating performance for the September quarter.

The drugmaker's net profit fell 24% year-on-year to ₹20 crore, compared to ₹26 crore in the same period last year.

Revenue marginally rose by 1.4% to ₹163.4 crore from ₹161.2 crore in the base quarter.

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) declined 10.2% to ₹25.4 crore, while the EBITDA margin slipped to 15.5% from 17.6% last year.

Lincoln Pharma shares are now trading 2.05% lower at ₹518.95. The stock is down 40% so far in 2025.

See Full Page